Antiatherogenic effects of vitamin E: The search for the Holy Grail

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 767-774

  Kirmizis, Dimitrios ^a   Chatzidimitriou, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anti inflammatory; Antioxidant; Atherosclerosis; Cardiovascular disease; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; BETA TOCOPHEROL; C REACTIVE PROTEIN; CYTOKINE; DELTA TOCOPHEROL; GAMMA TOCOPHEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIATHEROGENIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTIFICIAL KIDNEY; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LIPID PEROXIDATION; OXIDATIVE STRESS; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 74049104122     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s5532     Document Type: Review

References (68)

1. Steinberg D. Oxidative modification of LDL and Atherogenesis. Circulation. 1997;95:1062-1071.
2. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
3. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease: a critical review of epidemiologic and clinical trial data. Ann Intern Med. 1995;123:860-872.
4. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991;53(1 Suppl):326S-334S.
5. Riemersma RA, Wood DA, Macintyre CC, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet. 1991;337:1-5.
6. Singh RB, Ghosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol. 1995;76:1233-1238.
7. Mezzetti A, Zuliani G, Romano F, et al. Associazione Medica Sabin. Vitamin E and lipid peroxide plasma levels predict the risk of cardiovascular events in a group of healthy very old people. J Am Geriatr Soc. 2001;49:533-537.
8. Armstrong BK, Mann JI, Adelstein AM, Eskin F. Commodity consumption and ischemic heart disease mortality, with special reference to dietary practices. J Chronic Dis. 1975;28:455-469.
9. Feki M, Souissi M, Mokhtar E, et al. Vitamin E and coronary heart disease in Tunisians. Clin Chem. 2000;46:1401-1405.
10. Verlangieri AJ, Kapeghian JC, el-Dean S, Bush M. Fruit and vegetable consumption and cardiovascular mortality. Med Hypotheses. 1985;16:7-15.
11. Singh RB, Ghosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol. 1995;76:1233-1238.
12. Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am J Cardiol. 1996;77:232-236.
13. Rapola JM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, doubleblind, controlled trial. JAMA. 1996;275:693-698.
14. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
15. Virtamo J, Rapola JM, Ripatti S, et al. Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med. 1998;158:668-675.
16. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154-160.
17. De Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95.
18. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
19. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
20. Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem. 2004;11:1113-1133.
21. Holvoet P. Endothelial dysfunction, oxidation of low-density lipoprotein, and cardiovascular disease. Ther Apher. 1999;3:287-293.
22. Verlangieri AJ, Bush MJ. Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J Am Coll Nutr. 1992;11:131-138.
23. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: Effect of vitamin E. Am Heart J. 1993;125:958-973.
24. Upston JM, Terentis AC, Morris K, Keaney Jr JF, Stocker R. Oxidized lipid accumulates in the presence of alpha-tocopherol in atherosclerosis. Biochem J. 2002;363:753-760.
25. Suarna C, Wu BJ, Choy K, et al. Protective effect of vitamin E supplements on experimental atherosclerosis is modest and depends on preexisting vitamin E deficiency. Free Radic Biol Med. 2006;41: 722-730.
26. Berr C, Richard MJ, Roussel AM, Bonithon-Kopp C; for the EVA study group. Systemic Oxidative Stress and Cognitive Performance in the Population-Based EVA Study. Free Radic Biol Med. 1998;24:1202-1208.
27. Kritchevsky SB, Shimakawa T, Tell GS, et al. Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation. 1995;92:2142-2150.
28. Winder AF. Antioxidants, cholesterol, and ischaemic heart disease: CHAOS or confusion? J Clin Pathol. 1997;50:269-270.
29. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza n'nfarto miocardico. Lancet. 1999;354:447-455.
30. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-1218.
31. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164:1552-1556.
32. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-2023.
33. Serbinova EA, Packer L. Antioxidant properties of α-tocopherol. Methods Enzymol. 1994;234:354-366.
34. Wright ME, Lawson KA, Weinstein SJ, et al. Higher baseline serum concentrations of vitamin E are associated with lower total and cause-specific mortality in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 2006;84:1200-1207.
35. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330:1029-1035.
36. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
37. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
38. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680-2690.
39. Kirmizis D. Inflammatory reaction and oxidative stress in patients on chronic haemodialysis. PhD Thesis. Thessaloniki, Greece; Aristotle University; 2009.
40. Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels. 2008;23:249-256.
41. Annuk M, Zilmer M, Lind L, Linde T, Fellström B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747-2752.
42. Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis. 2003;42:286-294.
43. Gallucci MT, di Villahermosa SM, Maccarrone M. Vitamin E, 5-lipoxygenase and oxidative stress in haemodialysis patients: facts, not fancies. Nephrol Dial Transplant. 2008;23:772-773.
44. Yang CC, Hsu SP, Wu MS, Hsu SM, Chien C-T. Effects of vitamin C infusion and vitamin E-coated membrane on hemodialysis-induced oxidative stress. Kidney Int. 2006;69:706-714.
45. Morena M, Cristol JP, Descomps B, Canaud B. Does vitamin E bound on dialysis membrane improve the LDL susceptibility to oxidation? Lessons from an in vitro model. Contrib Nephrol. 1999;127:128-138.
46. Galli F, Rovidati S, Chiarantini L, Campus G, Canestrari F, Buoncristiani U. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int. 1998;54:580-589.
47. Mune M, Yukawa S, Kishino M, et al. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int. 1999;71(Suppl):S126-S129.
48. Girndt M, Lengler S, Kaul H, Sester U, Sester M, Khler H. Prospective crossiver trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis. 2000;35:95-104.
49. Tarng DC, Huang TP, Liu TY, Chen HW, Sung YJ, Wei YH. Effect of vitamin E-bonded membrane on the 8-hydroxy 2′-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 2000;58:790-799.
50. Eiselt J, Racek J, Trefil L, Opatrny K Jr. Effects of a vitamin E-modified dialysis membrane and vitamin C infusion on oxidative stress in hemodialysis patients. Artif Organs. 2001;25:430-436.
51. Satoh M, Yamasaki Y, Nagake Y, et al. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int. 2001;59:1943-1950.
52. Clermont G, Lecour S, Cabanne JF, et al. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med. 2001;31:233-241.
53. Tsuruoka S, Kawaguchi A, Nishiki K, et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis. 2002;39:127-133.
54. Usberti M, Gerardi G, Micheli A, et al. Effects of a vitamin E-bonded membrane and of glutathione on anemia and erythropoietin requirements in hemodialysis patients. J Nephrol. 2002;15:558-564.
55. Pertosa G, Grandaliano G, Soccio M, Martino C, Gesualdo L, Schena FP. Vitamin E-modified filters modulate Jun N-terminal kinase activation in peripheral blood mononuclear cells. Kidney Int. 2002;62:602-610.
56. Hara T, Takahashi N, Kiyomoto H, et al. Reduction of oxidized low-density lipoprotein by the long-term use of vitamin E-coated dialyzers in hemodialysis patients. Dial Transplant. 2004;33:197-207.
57. Betjes MG, Hoekstra FM, Klepper M, Postma SM, Vaessen LM. Vitamin E-coated dialyzer membranes downregulate expression of monocyte adhesion and co-stimulatory molecules. Blood Purif. 2004;22:510-517.
58. Morimoto H, Nakao K, Fukuoka K, et al. Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant. 2005;20:2775-2782.
59. Baragetti I, Furiani S, Vettoretti S, et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif. 2006;24:369-376.
60. Libetta C, Zucchi M, Gori E, et al. Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int. 2004;65:1473-1481.
61. Singh U, Devaraj S. Vitamin E: inflammation and atherosclerosis. Vitam Horm. 2007;76:519-549.
62. Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopherol transfer protein. Nat Genet. 1995;9:141-145.
63. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr. 2005;25:151-174.
64. Devaraj S, Tang R, Adams-Huet B, et al. Effect of high-dose alpha-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease. Am J Clin Nutr. 2007;86:1392-1398.
65. Taccone-Gallucci M, Manca-di-Villahermosa S, Battistini L, Stuffler RG, Tedesco M, Maccarrone M. N-3 PUFAs reduce oxidative stress in ESRD patients by inhibiting 5-lipoxygenase activity. Kidney Int. 2006;69:1450-1454.
66. Ridker PM, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) Investigators. Circulation. 1999;100:230-235.
67. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J. 1992;288:341-344.
68. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends Biochem Sci. 1999;24:219-223.